19,903 Shares in OrthoPediatrics Corp. (NASDAQ:KIDS) Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC acquired a new stake in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,903 shares of the company's stock, valued at approximately $461,000. Cubist Systematic Strategies LLC owned 0.08% of OrthoPediatrics at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Northern Trust Corp raised its position in shares of OrthoPediatrics by 0.3% in the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company's stock valued at $4,492,000 after purchasing an additional 644 shares during the period. Tudor Investment Corp ET AL raised its position in shares of OrthoPediatrics by 177.5% in the fourth quarter. Tudor Investment Corp ET AL now owns 66,486 shares of the company's stock valued at $1,541,000 after purchasing an additional 42,526 shares during the period. Dimensional Fund Advisors LP raised its position in shares of OrthoPediatrics by 29.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company's stock valued at $15,576,000 after purchasing an additional 152,681 shares during the period. Wasatch Advisors LP raised its position in shares of OrthoPediatrics by 47.2% in the fourth quarter. Wasatch Advisors LP now owns 696,318 shares of the company's stock valued at $16,141,000 after purchasing an additional 223,217 shares during the period. Finally, Barclays PLC raised its position in shares of OrthoPediatrics by 12.2% in the fourth quarter. Barclays PLC now owns 28,390 shares of the company's stock valued at $658,000 after purchasing an additional 3,092 shares during the period. 69.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Fred Hite sold 6,443 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $160,172.98. Following the sale, the chief financial officer now directly owns 207,989 shares in the company, valued at approximately $5,170,606.54. This trade represents a 3.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $132,006.60. Following the completion of the sale, the general counsel now owns 110,767 shares in the company, valued at approximately $2,753,667.62. The trade was a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,732 shares of company stock worth $589,978 over the last ninety days. Corporate insiders own 32.70% of the company's stock.

OrthoPediatrics Stock Performance

NASDAQ:KIDS traded down $0.23 during mid-day trading on Thursday, reaching $21.62. 13,688 shares of the company's stock were exchanged, compared to its average volume of 196,078. The firm has a market capitalization of $525.06 million, a PE ratio of -17.54 and a beta of 1.09. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. OrthoPediatrics Corp. has a one year low of $20.25 and a one year high of $35.99. The business's fifty day simple moving average is $22.70 and its two-hundred day simple moving average is $23.90.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). The firm had revenue of $52.41 million for the quarter, compared to analyst estimates of $51.68 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. Analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on KIDS. Stifel Nicolaus dropped their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, March 5th. Truist Financial lowered their price target on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 price target on shares of OrthoPediatrics in a research report on Thursday, May 8th. Piper Sandler lowered their price target on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Finally, Lake Street Capital initiated coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They set a "buy" rating and a $37.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, OrthoPediatrics currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.83.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.